Literature DB >> 11444500

Nonselective endothelin receptor antagonist initiated soon after the onset of myocardial infarction may deteriorate 24-hour survival.

C Takahashi1, Y Kagaya, S Namiuchi, M Takeda, M Fukuchi, H Otani, M Ninomiya, Y Yamane, M Kohzuki, J Watanabe, K Shirato.   

Abstract

To investigate the effects of endothelin blockade initiated immediately after the onset of myocardial infarction on survival and left ventricular remodeling, treatment with the nonselective receptor antagonist TAK-044 (n = 22) or saline (n = 19) for 3 weeks was initiated immediately after coronary ligation in rats. The 24-h survival rate was significantly lower in the TAK-044 group than in the saline group. The systolic blood pressure 24 h after the onset of myocardial infarction was similar in the saline and TAK-044 groups, although it was significantly lower in the TAK-044 group during the 3-week protocol. Heart weight/tibial length was significantly increased in the TAK-044 group compared with the saline group. As all deaths in the TAK-044 group occurred within 24 h after myocardial infarction, we performed additional experiments using a separate group of rats 12-16 h after myocardial infarction. Plasma and myocardial endothelin-1 levels were significantly increased, and a bolus injection of TAK-044 significantly reduced left ventricular dP/dtmax in these rats that had had a myocardial infarction compared with sham-operated rats. Endothelin receptor blockade initiated immediately after the onset of myocardial infarction may deteriorate acute-phase survival and left ventricular remodeling. Inhibition of the positive inotropic action of endothlin-1 may partially explain the increased 24-h mortality.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11444500     DOI: 10.1097/00005344-200107000-00004

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  4 in total

Review 1.  Current concepts for the neurohormonal management of left ventricular dysfunction after myocardial infarction.

Authors:  Keyur B Shah; Stephen S Gottlieb
Journal:  Curr Heart Fail Rep       Date:  2004-12

2.  Clinical trials of endothelin antagonists in heart failure: publication is good for the public health.

Authors:  N F Kelland; D J Webb
Journal:  Heart       Date:  2007-01       Impact factor: 5.994

3.  Cardiac myofibroblasts isolated from the site of myocardial infarction express endothelin de novo.

Authors:  Laxmansa C Katwa
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-05-08       Impact factor: 4.733

4.  Endothelin-1 is not predictive of ventricular ectopy or ventricular fibrillation during acute myocardial ischemia.

Authors:  Atman P Shah; James T Niemann; Scott Youngquist; Gary Josephson; John P Rosborough
Journal:  J Interferon Cytokine Res       Date:  2008-11       Impact factor: 2.607

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.